长春高新：子公司收到《药物临床试验批准通知书》

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for the injection of GenSci139 in patients with advanced solid tumors [1] Group 1 - The approval includes a clinical trial notification for the drug GenSci139 [1] - The clinical trial will focus on patients suffering from advanced solid tumors [1]